ASH 2017 | MUK Nine b: OPTIMUM, paving the way to effectively treat newly diagnosed high-risk MM
Due to constraints within the NHS treatment pathway, patients with newly diagnosed multiple myeloma (MM) who are characterized as having high-risk (HR) disease face many challenges in receiving intensive treatment. Described as a “novelty”, the Myeloma UK (MUK) Nine b: OPTIMUM Treatment Protocol (NCT03188172) is the first UK trial to offer precision medicine for MM patients with HR disease. Here, Martin Kaiser, MD, of The Royal Marsden Hospital NHS Foundation Trust, London, UK, explains the rationale behind the MUK Nine b trial and discusses the use of genetic markers as tools to identify patients who have HR disease. With the chance of receiving novel combination therapy, could patients in the UK with HR MM receive more effective treatment? This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
